|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.785 EUR | +0.37% |
|
+9.79% | +2.18% |
| May. 14 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
| Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 |
Nanobiotix S.A. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported revenue was EUR 3.29 million compared to EUR 1.33 million a year ago. Net loss was EUR 28.1 million compared to EUR 26.36 million a year ago.
Basic loss per share from continuing operations was EUR 0.8 compared to EUR 0.76 a year ago. Diluted loss per share from continuing operations was EUR 0.8 compared to EUR 0.76 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.18% | 347M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.47% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| -1.62% | 11.98B |
NANOBIOTIX 
